AntriaBio

AntriaBio is a biopharmaceutical company with a platform to develop novel extended release therapies. Our platform combines proprietary formulation and manufacturing capabilities with well-known molecules to significantly improve standards of care. AntriaBio's lead product candidate is AB101, an injectable once-weekly basal insulin for type 1 and type 2 diabetes that addresses a $11 billion market where the current standard of care is a once-daily basal insulin injection. We believe that our development strategy increases the probability of technical success while reducing safety and efficacy concerns, approval risks, and overall development costs. We also believe that our approach will result in significantly improved and more efficacious therapies with substantial benefits to the global diabetic population.
Type
Public
HQ
Louisville, US
Founded
2010
Employees
19 (est)
AntriaBio was founded in 2010 and is headquartered in Louisville, US

AntriaBio Locations

Louisville, US

AntriaBio Metrics

AntriaBio Summary

Market capitalization

$53.2 M

Closing share price

$1.3
AntriaBio's latest market capitalization is $53.2 M.

AntriaBio Market Value History

21% of current employees of AntriaBio are female and 79% are male.

AntriaBio Online Presence

AntriaBio Company Life

You may also be interested in